{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:47Z","timestamp":1791828587918,"version":"4.3.4"},"reference-count":54,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with upadacitinib 15 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data (cutoff: August 15, 2022) from five clinical trials in PsA (2), radiographic axSpA (r\u2010axSpA; previously ankylosing spondylitis) (2), and nonradiographic axSpA (nr\u2010axSpA) (1) were analyzed. Treatment\u2010emergent adverse events of EMMs including uveitis, inflammatory bowel disease (IBD), and psoriasis were assessed in patients treated with placebo, upadacitinib 15 mg, or adalimumab (PsA only) and are reported as exposure\u2010adjusted event rates (events per 100 patient\u2010years [E\/100 PY]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most patients (87.1%\u201399.3%) did not have a history of EMMs at baseline. In PsA, development of uveitis and IBD were low regardless of treatment or prior EMM history; rates were similar with upadacitinib 15 mg and adalimumab. In r\u2010axSpA, development of uveitis was numerically lower (E\/100 PY) in patients treated with upadacitinib 15 mg (2.8) versus placebo (7.5) and in patients with no history of uveitis (upadacitinib 15 mg 0.6; placebo 1.2) versus a history of uveitis (upadacitinib 15 mg 2.1; placebo 6.2); occurrence of IBD and psoriasis were low regardless of treatment or history. In nr\u2010axSpA, development of uveitis was low regardless of history but was numerically lower in patients treated with upadacitinib 15 mg (0.9) versus placebo (2.1); occurrence of IBD and psoriasis were low or absent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r\u2010axSpA. Regardless of treatment in r\u2010axSpA, having a history of uveitis appeared to predispose patients for future uveitis events.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art43069-toc-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43069","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:44:03Z","timestamp":1733197443000},"page":"536-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of Extramusculoskeletal Manifestations in Upadacitinib\u2010Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada, and Charit\u00e9\u2010Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumik","family":"Parikh","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-974X","authenticated-orcid":false,"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[{"name":"Ghent University Hospital and Ghent University  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro\u2010Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, IdiPAZ  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[{"name":"University of Glasgow  Glasgow United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-3176","authenticated-orcid":false,"given":"Michael","family":"Paley","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine  St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Coombs","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Biljan","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Nakasato","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wung","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[{"name":"University of Molise  Campobasso Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2012.01.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1093-z"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa062"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075754"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150630"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2\u2010year results from the multicenter phase IV C\u2010VIEW study","volume":"13","author":"Horst\u2010Bruinsma IE","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38873"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092585"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22848"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220420"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20972610"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.021"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1089099"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S433367"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.08.002"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9460187"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200207000-00001"},{"key":"e_1_2_8_31_1","unstructured":"SieperJ van derHeijdeD VarothaiNA et al.Comparison of baseline extra\u2010articular manifestations comorbidities and long\u2010term safety in patients treated with adalimumab for ankylosing spondylitis and non\u2010radiographic axial spondyloarthritis. Abstract presented at: American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Annual Meeting; November 14\u201019 2014; Boston MA."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"e_1_2_8_33_1","unstructured":"SrivastavaSK WatkinsTR NguyenQD et al.A phase 2 randomized controlled trial of the Janus kinase (JAK) inhibitor filgotinib in patients with noninfectious uveitis. Abstract presented at: ARVO Annual Meeting; May 1\u20104 2022; Denver CO and virtual."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex345"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2018.17"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000619"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.969368"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052092"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00486-1"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12207"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0239-y"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.03.002"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2081584"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225933"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22669"},{"key":"e_1_2_8_50_1","first-page":"438","article-title":"Management of concomitant inflammatory bowel disease or uveitis in patients with psoriatic arthritis: an updated review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Jadon DR","year":"2023","journal-title":"J Rheumatol"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00984-8"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24175"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa692"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.083725"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:35:39Z","timestamp":1759955739000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/art.43069"],"URL":"https:\/\/doi.org\/10.1002\/art.43069","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"2024-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}